Cancer Immunology, Immunotherapy

, 58:553

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes

  • Régis Bouquié
  • Annabelle Bonnin
  • Karine Bernardeau
  • Amir Khammari
  • Brigitte Dréno
  • Francine Jotereau
  • Nathalie Labarrière
  • François Lang
Original Article

DOI: 10.1007/s00262-008-0578-2

Cite this article as:
Bouquié, R., Bonnin, A., Bernardeau, K. et al. Cancer Immunol Immunother (2009) 58: 553. doi:10.1007/s00262-008-0578-2

Abstract

HLA multimers are now widely used to stain and sort CD8 T lymphocytes specific for epitopes from viral or tumoral antigens presented in an HLA class I context. However, the transfer of this technology to a clinical setting to obtain clinical grade CD8 T lymphocytes that may be used in adoptive cell transfer (ACT) is hindered by two main obstacles: the first obstacle is the use of streptavidin or derived products that are not available in clinical grade to multimerize HLA/peptide monomers and the second is the reported high degree of apoptosis that eventually occurs when T cell receptors are crosslinked by HLA multimers. In the present report, we describe new HLA multimers composed of immunomagnetic beads covalently coupled to a mAb specific for the AviTag peptide and coated with HLA/peptide monomers bearing the non biotinylated AviTag at the COOH terminus of the HLA heavy chain. Thus, all the components of this new reagent can be obtained in clinical grade. We compared these new multimers with the previously described multimers made with streptavidin beads coated with biotinylated HLA/peptide monomers, in terms of sorting efficiency, recovery of functional T cells, apoptosis and activation. We provide evidence that the new multimers could very efficiently sort pure populations of T lymphocytes specific for three different melanoma antigens (Melan-A, gp100 and NA17-A) after a single peptide stimulation of melanoma patients’ PBMC. The recovered specific T cells were cytotoxic against the relevant melanoma cell-lines and, in most cases, produced cytokines. In addition, in marked contrast with streptavidin-based multimers, our new multimers induced very little apoptosis or activation after binding specific T lymphocytes. Altogether, these new multimers fulfill all the necessary requirements to select clinical grade T lymphocytes and should facilitate the development of ACT protocols in cancer patients.

Keywords

ImmunotherapyCell-sortingHLA multimersMelanomaT lymphocytes

Abbreviations

ACT

Adoptive cell therapy

AICD

Activation induced cell death

CMV

Cytomegalovirus

EBV

Epstein–Barr virus

GMP

Good manufacturing practice

CTL

Cytotoxic T lymphocyte

DC

Dendritic cell

HLA

Human leucotyte antigen

PBMC

Peripheral blood mononuclear cells

TCR

T cell receptor

TIL

Tumor inflitrating lymphocyte

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Régis Bouquié
    • 1
  • Annabelle Bonnin
    • 1
  • Karine Bernardeau
    • 1
  • Amir Khammari
    • 2
  • Brigitte Dréno
    • 1
    • 2
  • Francine Jotereau
    • 1
    • 3
  • Nathalie Labarrière
    • 1
  • François Lang
    • 1
    • 4
  1. 1.INSERM U892Nantes Cedex 1France
  2. 2.CHU of Nantes, Unit of Skin CancerNantesFrance
  3. 3.Faculté des SciencesUniversité de NantesNantesFrance
  4. 4.UFR des Sciences PharmaceutiquesUniversité de NantesNantesFrance